The relationship between MnSOD Val16Ala gene polymorphism and the level of serum total antioxidant capacity with the risk of chronic kidney disease in type 2 diabetic patients: a nested case-control study in the Tehran lipid glucose study

Table 2 Adjusted OR for the CKD according to genotype, dominant model and allele of MnSOD Val16Ala genotype

Polymorphism	Genotype	CKD N (%)	Non-CKD N (%)	OR (95% CI)	P Value
MnSOD Val16Ala (rs4880)	Genotype
	Val/Val	85 (30.4%)	57 (20.4%)	1 (ref.)
	Ala/Val	158 (56.4%)	161 (57.5%)	0.65 (0.44–0.98)	0.041
	Ala/Ala	19 (6.8%)	42 (15%)	0.30 (0.16–0.57)	0.001
	Dominant Genotype Model
	Val/Val	177 (63.2%)	203 (72.5%)	1 (ref.)	0.006
	Ala/Ala + Ala/Val	85 (30.4%)	57 (20.4%)	0.55 (0.36–0.84)	0.006
	Allele
	Val	328 (62.6%)	275 (52.88%)	1 (ref.)	0.004
	Ala	196 (37.4%)	245 (47.12%)	0.53 (0.35–0.82)	0.004

ORs (odds ratios and 95% confidence intervals) were calculated using multivariate logistic regression analysis adjusted for BMI, energy intake, total Cholesterol, LDL-Cholesterol, triglyceride, Systolic and Diastolic blood pressure, smoking status and medication; CKD chronic kidney disease. CKD was defined as estimated glomerular filtration rate < 60 ml/min/1.73 m2. eGFR estimated glomerular filtration rate, MnSOD Manganese superoxide dismutase

ISSN: 1743-7075